Our robust pipeline comprises high value proprietary assets.
To create and capture the value of our pipeline we have built a strong, vibrant network between academia and various strategic partners, enabling us to leverage their strengths and capabilities, alongside our own, to progress our pipeline safely and expediently through the clinic.
NVG-222
NVG-222 is the first molecule to be equipped with our proprietary AutoRegulation (AR) platform technology. Building on the clinical success of our first generation TCE, this half-life-extended antibody uses a clinically validated targeting arm but is uniquely designed to self-inactivate in response to T cell overactivation. This groundbreaking technology provides precision control of the immune response, preventing the risk of severe toxicities and improving long-term cellular fitness and treatment efficacy.
In partnership with Cancer Research UK’s Centre for Drug Development, NVG-222 is positioned to establish the clinical proof-of-concept for the AR platform in both haematological malignancies and solid tumours.
NVG-666
NVG-666 is an AR-enabled TCE for the treatment of autoimmune diseases (AID). By targeting CD19-positive cells, it eliminates autoreactive B cells implicated in the progression of these disorders, leading to deep B-cell depletion and immune reset. The inclusion of the AR platform technology prevents the mode-of-action-related toxicities observed with higher doses of conventional T cell therapies, allowing for its potential use in the outpatient setting, a significant advantage over current-generation treatments. This is a key distinguishing feature of our technology.
Further reading
Our technologies
We are changing the paradigm of cancer therapy with our immunotherapy technology
Patients and families
We work with families and patient organisations to ensure our programmes deliver the best treatments for patients
